ArticleJournal of neurology2021
Manifold learning for amyotrophic lateral sclerosis functional loss assessment : Development and validation of a prognosis model.
Article in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic models for amyotrophic lateral sclerosis: a systematic review.Journal of neurology · 2021Pooled it
- Learning a distance for the clustering of patients with amyotrophic lateral sclerosis.BioData mining · 2026Article
- Driving with Motor Neuron Disease: Disease-Specific Considerations, Multi-Domain Assessments and Support Strategies.Brain sciences · 2026Review
- Evaluating the predictive potential of Th1 (IFN-γJournal of neurology · 2025Article
- New developments in imaging in ALS.Journal of neurology · 2025Review
- Update on recent advances in amyotrophic lateral sclerosis.Journal of neurology · 2024Review
- Detecting bulbar amyotrophic lateral sclerosis (ALS) using automatic acoustic analysis.Biomedical engineering online · 2024Article
- Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers.Journal of neurology · 2023Article
- Digital Alternative Communication for Individuals with Amyotrophic Lateral Sclerosis: What We Have.Journal of clinical medicine · 2023Review
- Brainstem-cortex disconnection in amyotrophic lateral sclerosis: bulbar impairment, genotype associations, asymptomatic changes and biomarker opportunities.Journal of neurology · 2023Article
- Hippocampal Metabolic Alterations in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Spectroscopy Study.Life (Basel, Switzerland) · 2023Article
- Leveraging process mining for modeling progression trajectories in amyotrophic lateral sclerosis.BMC medical informatics and decision making · 2023Article
- Machine-learning in motor neuron diseases: Prospects and pitfalls.European journal of neurology · 2022Article
- Deep learning methods to predict amyotrophic lateral sclerosis disease progression.Scientific reports · 2022Article
- Clusters of anatomical disease-burden patterns in ALS: a data-driven approach confirms radiological subtypes.Journal of neurology · 2022Article
- Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression.Journal of neurology · 2022Article
- Mapping cortical disease-burden at individual-level in frontotemporal dementia: implications for clinical care and pharmacological trials.Brain imaging and behavior · 2022Article
- Pathological neural networks and artificial neural networks in ALS: diagnostic classification based on pathognomonic neuroimaging features.Journal of neurology · 2022Article
- White matter microstructure alterations in frontotemporal dementia: Phenotype-associated signatures and single-subject interpretation.Brain and behavior · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) is an inexorably progressive neurodegenerative condition with no effective disease-modifying therapy at present. Given the striking clinical heterogeneity of the condition, the development and validation of reliable prognostic models is a recognised research priority. We present a prognostic model for functional decline in ALS where outcome uncertainty is taken into account. Patient data were reduced and projected onto a 2D space using Uniform Manifold Approximation and Projection (UMAP), a novel non-linear dimension reduction technique. Information from 3756 patients was included. Development data were sourced from past clinical trials. Real-world population data were used as validation data. Predictors included age, gender, region of onset, symptom duration, weight at baseline, functional impairment, and estimated rate of functional loss. UMAP projection of patients showed an informative 2D data distribution. As limited data availability precluded complex model designs, the projection was divided into three zones defined by a functional impairment range probability. Zone membership allowed individual patient prediction. Patients belonging to the first zone had a probability of [Formula: see text] (± [Formula: see text]) to have an ALSFRS score over 20 at 1-year follow-up. Patients within the second zone had a probability of [Formula: see text] (± [Formula: see text]) to have an ALSFRS score between 10 and 30 at 1 year follow-up. Finally, patients within the third zone had a probability of [Formula: see text] (± [Formula: see text]) to have an ALSFRS score lower than 20 at 1 year follow-up. This approach requires a limited set of features, is easily updated, improves with additional patient data, and accounts for results uncertainty. This method could therefore be used in a clinical setting for patient stratification and outcome projection.
Indexed as
Identifiers
32886252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.